

Further to the notice released on **02 December 2024** in relation to stock acquisition of Capitol Health (Australia, non-constituent) by Integral Diagnostics (Australia, constituent) in the Scheme of Arrangement, due to the latest announcement published by Capitol Health about the adjournment of the Court hearing until 10 December 2024, please be advised that the index treatment previously announced will be postponed and Integral Diagnostics (Australia, BYV2ZK7) will remain in the index with an **unchanged** shares in issue total of 233,961,997 and an **unchanged** investability weighting of 71.74853439% effective 06 December 2024.

Please see the revised notice below.

## Integral Diagnostics (Australia): Stock Acquisition of Capitol Health (Australia) - IMPORTANT UPDATE - WITHDRAWN Changes in FTSE Australian Equity Index Series

04 December 2024

Due to the adjournment of Court hearing to the scheme of arrangement in relation to the Stock Acquisition of Capitol Health (Australia, non-constituent) by Integral Diagnostics (Australia, constituent) until 10 December 2024, please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
FTSE Australia 300 Index	06 December 2024
FTSE Australia Mid/Small Cap 200 Index	06 December 2024
FTSE Australian Small Cap Companies Index	06 December 2024
FTSE Australia All-Share Index	06 December 2024

Please note that the date of the Court hearing on the approval of the Scheme of Arrangement has postponed to 10 December 2024. FTSE Russell will issue a further notice in due course.

For further information please contact FTSE Russell Client Services at [info@ftserussell.com](mailto:info@ftserussell.com) or call:

Australia	+61 (0) 2 7228 5659
Hong Kong	+852 2164 3333
Japan	+81 3 6441 1430
London	+44 (0) 20 7866 1810
New York	+1877 503 6437

Alternatively please visit our website at [lseg.com/ftse-russell](https://lseg.com/ftse-russell)